Structures and energetics of darunavir and active site amino acids of native and mutant HIV–1 protease: a computational study

被引:0
作者
Y. Indra Neela
Lalitha Guruprasad
机构
[1] University of Hyderabad,School of Chemistry
来源
Structural Chemistry | 2022年 / 33卷
关键词
Darunavir; HIV–1 protease; Mutation; Asp–25; Asp–30; HOMO; LUMO; ESP; NBO;
D O I
暂无
中图分类号
学科分类号
摘要
Quantum chemical calculations have been performed at the M06–2X/6–31G(d,p) level of theory to investigate the strength and nature of interactions between the active site amino acids at positions 25 and 30 with darunavir (DRV) inhibitor of two native (D25 and D30 in 4LL3, 1T3R) and five mutant (N25 in 3BVB, 3SO9; N30 in 2F80, 3LZV, 3UCB) HIV–1 proteases. Molecular orbitals HOMO and LUMO noted down upon the M06–2X/6–31G(d,p) level optimized amino acid–DRV geometries helped us explain which region of the inhibitor has the ability to interact with the amino acid more effectively. This analysis of the molecular orbitals allowed us to explore the nature of the interactions present between active site amino acids and the DRV in native and mutated proteins. The electrostatic potential surface maps generated for the amino acid–DRV complexes investigated the extent of interactions within the active site of the protein. Natural bond order analysis performed on the optimized geometries suggested that the extent of charge transfer helps in determining the stability of the complexes, which is very important for drug design.
引用
收藏
页码:395 / 407
页数:12
相关论文
共 241 条
[1]  
Alexander W(1998)Inhibitors of HIV–1 Protease: A major success of structure-assisted drug design Annu Rev Biophys Biomol Struct 27 249-284
[2]  
Jiri V(2003)HIV–1 Protease: Mechanism and Drug Discovery Org Biomol Chem 1 5-14
[3]  
Brik A(1989)Complete mutagenesis of the HIV–1 protease Nature 340 397-400
[4]  
Wong C-H(1990)Retroviral proteinases Curr Top Microbiol Immunol 157 153-185
[5]  
Loeb DD(1991)Deletion of sequences upstream of the proteinase improves the proteolytic processing of Human Immunodeficiency Virus Type 1 Proc Natl Acad Sci USA 88 4776-4780
[6]  
Swanstrom R(1995)p J Virol 69 6810-6818
[7]  
Everitt L(2013)Gag is required for particle production from full length Human Immunodeficiency Virus Type 1 molecular clones expressing protease Future Med Chem 5 1-23
[8]  
Manchester M(1996)Understanding HIV–1 protease autoprocessing for novel therapeutic development J Mol Biol 255 321-346
[9]  
Stamper SE(1995)Inhibition and catalytic mechanism of HIV-1 aspartic protease Nat Struct Biol 2 274-280
[10]  
Hutchison CA(2016)Flexibility and function in HIV–1 protease J Med Chem 59 5172-5208